The Estée Lauder Companies (ELC) is joining forces with biotechnology company Serpin Pharma to explore how their anti-inflammatory research can be applied in cosmetics.
Serpin Pharma identified a key portion of a superfamily of proteins called SERPINs (Serine Protease Inhibitors) that enhance the body’s natural ability to heal cells experiencing inflammation. The Virginia-headquartered company has engineered a small therapeutic peptide that boasts inflammatory and regenerative effects 300 times greater than that of its natural counterpart, Alfa-1 Antitrypsin (A1AT).
ELC thinks this innovative technology, which leverages the body’s innate immune response, could be harnessed to address skin irritation, aging, and sensitivity. Scientific studies are underway to demonstrate how Serpin’s technology can be applied to cosmetic products to rapidly and visibly reduce skin aging and irritation.
“In partnership with Serpin Pharma, we’re exploring powerful new biological pathways and cutting-edge biotech ingredients to rapidly mitigate visible skin irritation and sensitivity for our prestige beauty consumers worldwide,” said Carl Haney, Executive Vice President, Global Innovation and Research and Development (R&D), The Estée Lauder Companies.
